Browse News
Filter News
Found 758 articles
-
Preliminary Results for the Year Ended 31 December 2023
4/19/2024
Biodexa Pharmaceuticals PLC announces its audited preliminary results for the year ended 31 December 2023.
-
Redwood Scientific Technologies Inc.today announced a strategic shift in its product development priorities
4/18/2024
Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities.
-
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
4/8/2024
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the presentation of five abstracts at the American Association for Cancer Research (AACR), taking place from April 5-10, 2024, in San Diego, California.
-
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
3/28/2024
Biodexa Pharmaceuticals, an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma in pediatric patients and for Recurrent Glioblastoma in adults; two aggressive brain cancers with universally poor prognoses.
-
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
3/6/2024
Cardiff Oncology, Inc. (Nasdaq: CRDF) today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California.
-
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
2/29/2024
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the first patient was dosed in its randomized first-line Phase 2 trial, CRDF-004, for patients with RAS-mutated metastatic colorectal cancer (mCRC).
-
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
2/29/2024
Cardiff Oncology, Inc. (Nasdaq: CRDF) today provided a clinical update on the first release of data from its second-line RAS-mutated metastatic colorectal cancer (mCRC) ONSEMBLE trial.
-
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
2/29/2024
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
How Upcoming KRAS Inhibitors are Expected to Shape the Future Oncology Market Landscape?
2/26/2024
KRAS stands out as the most commonly altered among the trio of RAS genes, with NRAS and HRAS following suit. The human KRAS gene resides on chromosome 12p12.1 and comprises six exons, primarily positioned in exon 1 at sites 12 and 13, though occasionally found in codons 61, 63, 117, 119, and 146.
-
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
2/26/2024
Cardiff Oncology, Inc. (Nasdaq: CRDF) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024.
-
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
2/23/2024
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) announces an R&D update including positive top-line clinical trial results of a recently completed Phase 1 study of MTX110 in patients with diffuse midline glioma, or DMG, and results of a preclinical experiment designed to demonstrate tolimidone’s potential for beta cell proliferation in an in vitro model.
-
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
2/22/2024
Cardiff Oncology, Inc. today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29 after the close of trading.
-
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
2/8/2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX) today provided survival updates from its MAGIC-G1 study (NCT05324501) of MTX110 in patients with recurrent glioblastoma (“rGBM”) being conducted at Duke Cancer Institute and Baptist MD Anderson Cancer Center.
-
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
2/7/2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX) today announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled “Prevention of Pancreatic Cell Degeneration” which was exclusively licensed to Biodexa by Melior Pharmaceuticals, Inc., along with other patents, in a transaction which closed in December 2023.
-
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
1/22/2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024.
-
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
1/17/2024
Cardiff Oncology, Inc. today announced that the findings of the Phase 1b portion of the Phase 1b/2 study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC) disclosed by Cardiff Oncology in August 2023 have been published in the peer-reviewed journal Clinical Cancer Research, a journal of the American Association for Cancer Research.
-
Hemab Therapeutics Appoints Dr. Akshay Vaishnaw to Board of Directors and Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of Akshay Vaishnaw, MD, PhD, to its Board of Directors.
-
Biodexa Appoints Ann Merchant to the Board of Directors
12/29/2023
Biodexa Pharmaceuticals PLC is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023.
-
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
12/21/2023
Biodexa Pharmaceuticals PLC announced the closing of an underwritten public offering of units for gross proceeds of approximately $6.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Biodexa.
-
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
12/19/2023
Biodexa Pharmaceuticals PLC, today announced the pricing of an underwritten public offering of units.